Ask AI
ProCE Banner Activity

Our Thoughts on Recognizing and Managing Adverse Events Associated With Bispecific Antibodies in the Management of Patients With DLBCL

Clinical Thought

Read this commentary for practical insights from expert faculty for managing some expected challenges to the optimal clinical integration of bispecific antibodies into optimal care for patients with DLBCL due to treatment-related adverse events.

Released: May 07, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education, in partnership with Smart Patients, Inc.

ProCE Banner

Supporters

Supported by an educational grant from Genentech, a member of the Roche Group.

Genentech, a member of the Roche Group

Partners

Smart Patients, Inc.

ProCE Banner

Target Audience

This activity is intended for community hematology teams caring for patients with DLBCL, including medical oncologists, nurse practitioners, physician associates, pharmacists, nurses, and other healthcare professionals.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Differentiate high-risk features and unmet needs in newly diagnosed DLBCL to guide frontline treatment selection

  • Evaluate clinical trial data and guideline recommendations to effectively integrate bispecific antibodies into the management of relapsed or refractory DLBCL

  • Formulate multidisciplinary strategies to identify, prevent, and manage cytokine release syndrome and related toxicities associated with bispecific antibodies

  • Incorporate patient goals and preferences into shared decision-making to optimize DLBCL treatment planning across the continuum of care

Disclosure

Primary Author

Kathleen Dorritie, MD: researcher (paid to institution): Bristol Myers Squibb, Janssen, Kite.

Tycel J. Phillips, MD: advisory board: AbbVie, ADCT, BeiGene, Celgene/Bristol Myers Squibb, Genentech, Genmab, Lilly, Merck, Pharmacyclics, Seattle Genetics/Pfizer, Xencor; researcher: AbbVie, ADC, Bristol Myers Squibb, Genentech, Sobi; consultant: AbbVie, AstraZeneca, Bristol Myers Squibb, Caribou, Genentech, Gilead/Kite, Incyte, Ipsen, Janssen, Johnson & Johnson, Pfizer, Xencor.